Loading...
XASXVBS
Market cap2mUSD
Dec 23, Last price  
0.08AUD
1Q
-3.75%
IPO
-94.93%
Name

Vectus Biosystems Ltd

Chart & Performance

D1W1MN
XASX:VBS chart
P/E
—
P/S
3.60
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
17.87%
Rev. gr., 5y
453.09%
Revenues
1m
-15.94%
659,717872,2302,95175,06649,3371,82722051,1861801,300,0811,354,5351,138,674
Net income
-2m
L-32.21%
-1,237,890-1,482,108-1,655,850-3,211,000-3,794,254-2,587,296-1,596,280-2,996,071-3,861,244-3,993,775-3,448,860-2,338,124
CFO
-2m
L-13.60%
-1,122,042-1,293,422-1,640,884-2,610,599-3,893,059-1,387,102-1,040,613-3,001,547-3,255,532-4,441,231-2,352,742-2,032,806
Earnings
Feb 21, 2025

Profile

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure, which include treatments for heart, kidney, liver, and lung diseases. Its lead compound is VB0004, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.
URL
https://www.vectusbiosystems.com.au/
IPO date
Feb 23, 2016
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
1,139
-15.94%
1,355
4.19%
1,300
722,167.22%
Cost of revenue
3,409
6,239
5,910
Unusual Expense (Income)
NOPBT
(2,271)
(4,884)
(4,610)
NOPBT Margin
Operating Taxes
(1,061)
(1,288)
(1,300)
Tax Rate
NOPAT
(1,210)
(3,596)
(3,310)
Net income
(2,338)
-32.21%
(3,449)
-13.64%
(3,994)
3.43%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,475
BB yield
-21.21%
Debt
Debt current
29
43
5,946
Long-term debt
29
55
958
Deferred revenue
Other long-term liabilities
5
3
72
Net debt
(751)
(2,853)
5,622
Cash flow
Cash from operating activities
(2,033)
(2,353)
(4,441)
CAPEX
(68)
(17)
(21)
Cash from investing activities
(68)
(17)
(21)
Cash from financing activities
(41)
4,039
(35)
FCF
158
(4,473)
(4,439)
Balance
Cash
809
2,951
1,281
Long term investments
Excess cash
752
2,883
1,216
Stockholders' equity
1,486
3,524
(4,421)
Invested Capital
768
713
6,876
ROIC
ROCE
EV
Common stock shares outstanding
53,201
47,952
33,376
Price
0.08
-82.50%
0.44
-55.33%
0.99
-27.04%
Market cap
4,096
-80.58%
21,099
-35.82%
32,875
-13.56%
EV
3,345
18,246
38,497
EBITDA
(2,212)
(4,837)
(4,590)
EV/EBITDA
Interest
9
206
693
Interest/NOPBT